FOLH1 and Familial prostate cancer: Unlike conventional imaging, PET with 68Ga-PSMA offers the unique possibility of visualising prostate cancer residual disease or recurrence at very low prostate-specific antigen (PSA) levels with 58.3% of PET-positive results found in a PSA range of 0.51–1.0 ng/ml [11–16].